Ahmed Farid Gadelmawla

Dr. Ahmed Farid Gadelmawla

Menoufia University, Shibīn al Kawm, Al Minūfīyah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2025 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
AEAmr M. Abou Elezz
Amr M. Abou Elezz
KKKareem Khalefa
Kareem Khalefa
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
YKYoussef A. Khattab
Youssef A. Khattab
MZMohamed Abo Zeid
Mohamed Abo Zeid
Recent studies highlighted the relation between type 2 diabetes and Parkinson’s disease, suggesting a relation between insulin resistance and α-synuclein aggregation. Antidiabetic medications, including GLP-1 receptor agonists and PPAR-γ agonists, have shown potential neuroprotective effects. We conducted a comprehensive literature search retrieving randomized controlled trials (RCTs) comparing antidiabetic drugs and placebo. Key outcomes included motor and non-motor symptoms, along with the safety profile. Data were analyzed using RevMan, and trial sequential analysis as well as sensitivity analysis were conducted to ensure the robustness of our results. In addition, to ensure the reliability of our evidence, we conducted the GRADE evaluation approach. Seven RCTs, with 973 patients, were eligible for our inclusion criteria. Antidiabetic drugs have shown no significant difference from placebo concerning change in MDS-UPDRS scores while on medication in Parts I, II, III, IV (MD = −0.04, 95% CI [−0.74 to 0.66], p = 0.90), (MD = −0.88, 95% CI [−2.11 to 0.34], p = 0.16), (MD = −1.10, 95% CI [−2.61 to 0.42], p = 0.16), (MD = −0.09, 95% CI [−0.45 to 0.27], p = 0.64), respectively. However, for MATTIS-DRS and MADRS scores, results showed a significant difference favoring GLP-1 agonists (MD = 2.42, 95% CI [0.01 to 4.83], p = 0.05), (MD = −2.08, 95% CI [−3.93 to −0.23], p = 0.03) respectively. As for safety profile, results revealed significant differences favoring the placebo group. This meta-analysis concludes that antidiabetic drugs in early-to mid-stage Parkinson’s disease show no significant benefit considering non-motor symptoms detected by MDS-UPDRS I, with TSA confirming this finding as a conclusive result. Similarly, no notable effects on motor symptoms were observed, although future trials are needed. GLP-1 agonists revealed potential antidepressant effects as well as improving cognitive functions detected by MADRS and MATTIS-DRS, respectively. However, antidiabetic drugs were associated with higher risks of gastrointestinal adverse effects such as nausea, vomiting, and weight loss.

21 February 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
EBElsayed Balbaa
Elsayed Balbaa
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
AIAhmed Ibrahim
Ahmed Ibrahim
AMAlMothana Manasrah
AlMothana Manasrah
AEAhmed Elbataa
Ahmed Elbataa
ABAbdelhamid Ben‐Selma
Abdelhamid Ben‐Selma
Introduction: Concerns about diabetic ketoacidosis (DKA) and euglycemic ketoacidosis (eKA) are balanced against possible organ‐protective benefits in the debated perioperative management of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. This meta‐analysis compared the perioperative clinical and laboratory outcomes associated with perioperative exposure to SGLT2i. Methods: Through July 31, 2025, we searched PubMed, Web of Science, Scopus, and CENTRAL for observational studies and randomised controlled trials comparing the outcomes of preoperative use of SGLT2 inhibitors with non‐use in patients undergoing cardiac or non‐cardiac surgery. We pooled data using a random‐effects model and investigated heterogeneity using leave‐one‐out sensitivity analyses. PROSPERO‐ID: CRD420251155809. Results: There were 10 studies comprising 246,242 patients. Due to considerable heterogeneity, the primary pooled analysis revealed no significant association between SGLT2 inhibitor use and either eKA (OR 4.86; p = 0.11) or DKA (OR 2.21; p = 0.11). However, a significant increase in the risk of eKA (OR 1.11; p < 0.001) and DKA (OR 5.33; p < 0.001) was observed using leave‐one‐out sensitivity analysis to identify outliers. On the other hand, the usage of SGLT2 inhibitors was associated with a statistically significant decrease in both mortality (OR 0.73; p = 0.006) and acute renal injury (OR 0.68; p < 0.0001). The SGLT2 inhibitor group had significantly lower perioperative pH, base excess, and blood glucose levels. Conclusion: The use of perioperative SGLT2 inhibitors poses a clinical paradox between significant renoprotection and survival advantages and a latent risk of ketoacidosis concealed by considerable heterogeneity. While metabolic monitoring is essential, current surgeries requiring more prolonged withholding may need to weigh metabolic risk against the drug's significant benefit in reducing acute kidney injury and mortality.

19 June 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
AIAhmed Ibrahim
Ahmed Ibrahim
LSLaila Shalabi
Laila Shalabi
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
MHMohammed Tarek Hasan
Mohammed Tarek Hasan
RARahmeh Kamal Al-Asmar
Rahmeh Kamal Al-Asmar
AAAhmad Al-Qudimat
Ahmad Al-Qudimat

10 November 2025 in Pain Medicine
Verified
Journal Article
Closed access
AMAhmed Mansour
Ahmed Mansour
AAAhmed Mostafa Amin
Ahmed Mostafa Amin
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
AEAhmed Elbataa
Ahmed Elbataa
AMAnas Mansour
Anas Mansour
AAAlaa Abd-Elsayed
Alaa Abd-Elsayed
Background and Objective: Pregabalin (PGB) and duloxetine (DLX) are commonly used first-line medications in the clinical management of painful diabetic neuropathy (PDN), yet high-quality comparative evidence is limited. This meta-analysis evaluates the comparative efficacy and safety of PGB versus DLX, focusing on efficacy outcomes such as pain reduction and mental health, and safety outcomes including adverse events in PDN patients. Method: We searched electronic databases for relevant studies assessing the efficacy and safety of PGB and DLX in PDN. The primary outcomes were the mean change of the Visual Analog Scale (VAS) and the improvement ratio for patients achieving ≥ 50% pain reduction. Secondary outcomes include the Numeric Rating Scale (NRS) for pain, the Short Form 12 Health Survey (SF-12), and related adverse events. A random-effects meta-analysis was performed to evaluate these outcomes. Results: We analyzed 19 studies involving 4483 patients. PGB significantly reduced VAS scores at 24 weeks (MD = -0.38; 95% confidence interval [CI], -0.45 to -0.31; P < .0001) and decreased the mental component of SF-12 compared to DLX (MD = -3.36; 95% CI, -6.64 to -0.07; P = .05) and lower rates of achieving >50% pain reduction (risk ratio = 0.88; 95% CI, 0.79 to 0.98; P = .03). Regarding safety, PGB showed a lower incidence of several adverse events, including anorexia, decreased appetite, diarrhea, nausea, and vomiting. However, no significant differences in VAS scores were observed between PGB and DLX at 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, and 12 weeks, with similar results observed in NRS. Conclusion: We found that PGB and DLX showed similar efficacy in relieving PDN. Ultimately, the 2 drugs’ similar effectiveness and different safety profiles highlight the importance of considering patient-specific factors when choosing the appropriate treatment.

11 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Abdelrahman HafezAbdelrahman Hafez
Abdelrahman Hafez
AAAbdelaziz Abdelaziz
Abdelaziz Abdelaziz
AMAhmed Mansour
Ahmed Mansour
IKIbrahim Kamal
Ibrahim Kamal
ABAli Bakr
Ali Bakr
MEMohamed Elhelw
Mohamed Elhelw
Background/Objectives: Esaxerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising results in the treatment of essential hypertension (HTN). This study aims to comprehensively analyze the effectiveness of esaxerenone to control BP in patients with essential HTN. Methods: A systematic search was performed on PubMed, Scopus, Web of Science (WOS), and Cochrane Library from inception until January 2025 for randomized controlled trials (RCTs) comparing esaxerenone with standard HTN usual care. The primary outcome of interest was mean changes in sitting systolic (SBP) and diastolic blood pressure (DBP). Other secondary outcomes were mean changes in 24 h-SBP and 24 h-DBP, and target BP achievement. Safety outcomes, such as adverse events and increased levels of potassium/uric acid, were also assessed. Results: Our meta-analysis included four studies with a total of 1981 patients, all conducted in Japan. Esaxerenone demonstrated dose-dependent blood pressure reductions. At 5 mg, sitting DBP decreased by 4.22 mmHg (95% CI −8.72 to 0.29; p = 0.07) and SBP by 9.07 mmHg (95% CI −17.69 to −0.45; p = 0.04), while the 1.25 mg dose showed smaller, non-significant reductions. For 24 h measurements, only the 5 mg dose achieved significant reductions. Target BP achievement increased by 48% overall (RR 1.48, 95% CI 1.11 to 1.96; p = 0.007), with stronger effects at 5 mg (RR 2.05, 95% CI 1.03 to 4.08; p = 0.04). Esaxerenone significantly reduced nocturnal SBP by 10.62 mmHg (95% CI −14.01 to −7.23; p < 0.001). Conclusions: In patients with essential HTN, esaxerenone was shown to be safe and well-tolerated compared with usual care. Long-term data on safety is warranted.

11 September 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Open access
PDF file
AEAmr M. Abou Elezz
Amr M. Abou Elezz
KKKareem Khalefa
Kareem Khalefa
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
LTLamees Taman
Lamees Taman
HSHabiba Tariq Saeed
Habiba Tariq Saeed
MZMohamed Abo Zeid
Mohamed Abo Zeid
This study aims to evaluate the efficacy and safety of ensifentrine in COPD patients. Following the PRISMA guidelines, we conducted a systematic review and meta-analysis, systematically searching PubMed, Web of Science, Scopus, and Cochrane library up to 12 December 2024, for randomized controlled trials (RCTs) evaluating ensifentrine compared to placebo in COPD patients. Eligibility criteria included studies reporting outcomes such as pulmonary function tests, exacerbation rates, and adverse events. Subgroup analysis was conducted based on the timing of outcome evaluation and the doses administered. Additionally, a meta-regression model was employed to evaluate the possible correlations between the Ensifentrine doses and “Average forced expiratory volume (FEV 1)” results and identify the optimal dose. Trial sequential analysis (TSA) was implemented to ensure the conclusiveness of our results. Furthermore, the GRADE approach was used to assess the certainty of evidence and for quality assessment the RoB-2 tool was used. Four RCTs were included in our analysis with a total of 2370 COPD patients. Compared to placebo, ensifentrine 3 mg significantly improved lung functions as measured by change in average FEV1 (MD = 0.09, 95% CI: [0.07 to 0.12]), change in peak FEV1 (0–3 h) (MD = 0.15, 95% CI: [0.13 to 0.18]), and change in morning trough FEV1 (MD = 0.04, 95% CI: [0.02 to 0.07]). Subgrouping based on the administrated dose found that ensifentrine 3 mg showed higher, yet non-significant results compared to the included doses (0.75, 1.5, and 6 mg) in all pulmonary function tests. Moreover, meta-regression revealed a significant dose–response relationship for average FEV1 up to 3 mg, indicating optimal efficacy at 3-mg dose. Ensifentrine also significantly improved quality of life measures, with no significant increase in adverse events across doses. Ensifentrine has proven to be effective in improving lung functions and respiratory symptoms with an acceptable safety profile, thus suggesting a valuable addition to the management of COPD with consideration of potential adverse effects. Nevertheless, further studies with extended long-term follow-up are essential to fully assess the sustained efficacy and safety of ensifentrine and support its optimal therapeutic integration. Clinical trial number: Not applicable.